PODCAST
New Hot Flash Drug Hits NHS + The Menopause Marketing Explosion
April 6, 2026·8:05·Episode 8
Quick Summary
This episode covers the NHS approval of fezolinetant, a new non-hormone drug for hot flashes, the concerning surge in menopause product marketing, and breakthrough research on how menopause changes brain structure and function. Nykki discusses both the promise and pitfalls of the current menopause treatment landscape.
New Hot Flash Drug Hits NHS + The Menopause Marketing Explosion
0:000:00
Key Takeaways
- ✦Fezolinetant, a new non-hormone drug that blocks neurokinin 3 receptors, is now available on NHS and can reduce hot flash frequency by about half
- ✦The menopause product market is projected to reach $24 billion by 2030, but many products lack rigorous clinical testing
- ✦New research from 800+ women shows menopause causes measurable changes in brain structure and connectivity, particularly in areas controlling memory and executive function
- ✦Women with more severe cognitive symptoms during menopause are also more likely to experience depression and anxiety
- ✦Some brain changes during menopause may be adaptive, with brains developing new pathways to maintain function
Sources & References
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.